Sign In
Buy CLPT
$13.30
+0.93 (+7.52%)
At Close: Jun 03, 2026
ClearPoint Neuro (CLPT) Moves 8.1% Higher: Will This Strength Last?
09:20am, Monday, 09'th Mar 2026
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
08:00am, Friday, 06'th Mar 2026
SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the b
CLPT Gets EU MDR Certification for ClearPoint Navigation Software
08:56am, Tuesday, 27'th Jan 2026
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.
ClearPoint Neuro: From Validation To Scale
04:47am, Tuesday, 27'th Jan 2026
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains
ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software
11:16am, Friday, 23'rd Jan 2026
ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
08:30am, Monday, 12'th Jan 2026
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (th
Critical Survey: ClearPoint Neuro (NASDAQ:CLPT) vs. Sartorius (OTCMKTS:SARTF)
02:08am, Tuesday, 30'th Dec 2025
Sartorius (OTCMKTS:SARTF - Get Free Report) and ClearPoint Neuro (NASDAQ: CLPT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based
Investment strategist names 10 sub-$10 billion stocks to watch in 2026
03:32pm, Saturday, 13'th Dec 2025
Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.
ClearPoint Neuro Completes Acquisition of IRRAS
05:00pm, Thursday, 20'th Nov 2025
Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire
ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript
05:21pm, Wednesday, 12'th Nov 2025
ClearPoint Neuro, Inc. ( CLPT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Joseph Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Confere
ClearPoint Neuro: CRO Facility Should Reaccelerate Growth
03:55pm, Wednesday, 12'th Nov 2025
ClearPoint's third quarter results were weak, which was at least partly due to resource constraints while its new CRO facility was being opened. The near-term outlook for ClearPoint's biopharma busine
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Lags Revenue Estimates
07:16pm, Thursday, 06'th Nov 2025
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago.
ClearPoint Neuro Reports Third Quarter 2025 Results
04:55pm, Thursday, 06'th Nov 2025
Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire
ClearPoint Neuro Announces Agreement to Acquire IRRAS
04:50pm, Thursday, 06'th Nov 2025
Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment
